Evidence map›Paper›PMID 35962618›Full record

ReviewParasite immunology2023

Fungal resilience and host-pathogen interactions: Future perspectives and opportunities.

Alistair J P Brown

Open access · hybridAbstract readReview
In one paragraph

Review in Parasite immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 30 citations in OpenAlex.

  1. Review
  2. Early Cellular Responses ofAntibiotics (Basel, Switzerland) · 2026
    Article
  3. Compromising UDP-sugar nucleotide biosynthesis attenuatesCell surface (Amsterdam, Netherlands) · 2026
    Article
  4. Article
  5. The roles ofFrontiers in medicine · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Fungal Communities in Various Environments.Journal of fungi (Basel, Switzerland) · 2025
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Polypeptides TargetingJournal of fungi (Basel, Switzerland) · 2023
    Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Alistair J P BrownMedical Research Council Centre for Medical Mycology at the University of Exeter, Exeter, UK.ORCID 0000-0003-1406-4251
University of Exeter · GB

Funding

Medical Research Council MR/M026663/2Medical Research Council MR/V033417/1
6 · The paper itself

Abstract

We are constantly exposed to the threat of fungal infection. The outcome-clearance, commensalism or infection-depends largely on the ability of our innate immune defences to clear infecting fungal cells versus the success of the fungus in mounting compensatory adaptive responses. As each seeks to gain advantage during these skirmishes, the interactions between host and fungal pathogen are complex and dynamic. Nevertheless, simply compromising the physiological robustness of fungal pathogens reduces their ability to evade antifungal immunity, their virulence, and their tolerance against antifungal therapy. In this article I argue that this physiological robustness is based on a 'Resilience Network' which mechanistically links and controls fungal growth, metabolism, stress resistance and drug tolerance. The elasticity of this network probably underlies the phenotypic variability of fungal isolates and the heterogeneity of individual cells within clonal populations. Consequently, I suggest that the definition of the fungal Resilience Network represents an important goal for the future which offers the clear potential to reveal drug targets that compromise drug tolerance and synergise with current antifungal therapies.

Indexed as

Antifungal AgentsHost-Pathogen InteractionsVirulenceAntifungal Agentsantifungal drug resistanceantifungal immunityfungal pathogenicityfungal resiliencehost-pathogen interactionsmetabolic adaptationstress resistance

Identifiers

PMID35962618
PMCPMC10078341
OpenAlexW4291169794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.